drugset
drugset / Trial / NCT01840423

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers

NCT01840423 ↗

Phase 1 Completed 101 enrolled Orion Corporation, Orion Pharma
RandomizedCrossoverDouble-blind

Summary

The purpose of this study is to evaluate the safety and tolerability of escalating doses of ODM-104 when given to healthy male volunteers.

Timeline

Start
2013-05
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Entacapone Small molecule 200 mg Oral
Subject ODM-104 Unknown — Oral
Comparator levodopa/carbidopa Unknown — Oral

Indications

No indication recorded.